**Specifications Table**TableSubject area*Medicine*More specific subject area*Obstetrics & Gynecology*Type of data*Figures & table*How data was acquired*TOF-MS, HPLC-UV, LC-ESI(+)-MS/MS*Data format*Structural confirmation/purity & LC-MS/MS acquisition parameters*Experimental factors*None applied*Experimental features*TOF-MS for structural elucidation and HPLC-UV for purity assessment of synthetized GSA; LC-ESI(+)-MS/MS acquisition parameters for each biomarker*Data source location*Valencia, Spain*Data accessibility*Data are with this article*

1. Value of the data {#s0005}
====================

•GSA standard was synthetized and its molecular structure was confirmed by TOF-MS.•Purity of the GSA standard was assessed employing HPLC-UV.•LC-MS/MS for the simultaneous quantification of potential biomarkers in small sample volumes.•MRM acquisition enabling a highly specific and sensitive analytical response.•Linear response curves for each biomarker normalized by peak area values obtained from internal standard solutions for improved reproducibility.

2. Data, materials and methods {#s0010}
==============================

2.1. GSA standards {#s0015}
------------------

GSA was synthesized and purified as described by Harwood et al. [@bib2] by treating an aqueous GSH solution with hypochlorite solution in phosphate buffer (pH 7.4) at an equimolar ratio (100 mmol L^−1^) at room temperature. GSA was purified by manual collection of fractions from a Shimadzu Scientific Instruments (Columbia, MD, USA) high performance liquid chromatographic (HPLC) system equipped with a Halo C18 column (2.1×100 mm, 2.7 µm) from Advanced Materials Technology (Wilmington, DE, USA) and using an injection volume of 50 µL. Chromatograms were acquired using UV detection at 222 and 254 nm. Separation was achieved using an H~2~O (0.1% formic acid): methanol gradient and a flow rate of 0.5 mL min^−1^; gradient conditions were set as follows: from 0 to 3 min 2% methanol; from 3 to 6 min from 2% to 98% methanol; from 6 to 10 min 98% methanol; from 10 to 10.1 min from 98% to 2% methanol and from 10.1 to 14 min 2% methanol. The collected fractions were lyophilized to obtain a fluffy white powder which at −20 °C was stable over a period of several months. In the obtained fractions, the presence of GSA was confirmed by recording full scan direct infusion TOF-MS spectra employing an ABSciex 5600-Triple TOF-MS spectrometer (Framingham, MA, USA) operating in the ESI^+^ mode. [Fig. 1](#f0005){ref-type="fig"} shows a TOF-MS spectrum of a GSA containing fraction in the region between 250 and 400 m/z. Four peaks with intensities \>500 counts were identified and three of them could be assigned to the molecular ion of GSA and GSA adducts, respectively. The purity of the obtained GSA was determined from three independent runs to be 91±2% employing the above-described HPLC-UV method and measuring the GSA peak area vs. the total area under the curve in chromatograms recorded at 254 nm. [Fig. 2](#f0010){ref-type="fig"} shows chromatograms of a GSA containing fraction and a blank injection.

2.2. LC-MS/MS acquisition parameters for biomarker determination in AF samples {#s0020}
------------------------------------------------------------------------------

An Acquity -- Xevo TQ from Waters (Milford, MA, USA) operating in the ESI^+^ mode was used for the analysis of standard solutions and processed amniotic fluid samples (details can be found in [@bib1]). Parameters were set as follows: capillary voltage was 3.2 kV, source temperature was 150 °C, desolvation temperature was 395 °C, nitrogen cone and desolvation gas flows were 150 and 800 L h^−1^, respectively and the dwell time was 5 ms. For MS parameter optimization, individual standard solutions of each biomarker at a concentration of 1 µmol L^−1^ were injected. For LC separations, a Kinetex C8 column (100×2.1 mm, 1.7 µm) from Phenomenex was used running a gradient employing H~2~O (0.1% v/v formic acid) and acetonitrile (0.1% v/v formic acid) as mobile phases A and B with gradient conditions as follows: from 0 to 1.25 min 1% B; from 1.25 to 4.75 min the mobile phase composition changed from 1% to 98% B; from 4.75 to 5 min 98% B; from 5 to 5.1 min the gradient returned to its initial conditions of 1% B which were held until 6 min. Flow rate, column temperature and injection volume were set to 0.4 mL min^−1^, 45 °C and 2 µL, respectively. Samples were kept in the autosampler at 4 °C during batch analysis. Multiple reaction monitoring (MRM) was carried out employing the acquisition parameters summarized in [Table 1](#t0005){ref-type="table"}. MassLynx 4.1 and QuanLynx 4.1 from Waters (Milford, MA, USA) were used for data acquisition and processing, respectively. Linear response curves were calculated for each biomarker normalizing with peak areas of internal standards.
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![TOF-MS spectrum of GSA fraction. Note: Molecular formula of GSA: C10H15N3O8S, theoretical molecular weight of GSA: 337.05744.](gr1){#f0005}

![Chromatograms from a GSA containing fraction (triplicate injection) after purification and a blank injection.](gr2){#f0010}

###### 

LC-ESI(+)-MS/MS acquisition parameters.

Table 1.

  **Analyte**    ***m*/*z* parent ion**   **Cone \[V\]**   ***m*/*z* daughter ion**   **CE \[eV\]**
  -------------- ------------------------ ---------------- -------------------------- ---------------
  3NO~2~-Tyr     227.1                    25               181                        10
  3Cl-Tyr        216                      30               170                        15
  8OHdG          284                      30               168                        15
  GSA            338                      45               155.1                      25
  GSSG           613.2                    50               355                        35
  8OHdG-C13N15   284                      30               168                        15
  Phe-D5         171.5                    30               125                        20
  Meth-D3        153                      30               63.5                       25

CE: collision energy; 3NO~2~-Tyr: 3-nitro-tyrosine; 3Cl-Tyr: 3-chloro-tyrosine; 8OHdG: 8-hydroxy-2׳ -deoxyguanosine; GSA: glutathione sulfonamide; GSSG: oxidized glutathione; 8OHdG-C13N15: 8-hydroxy-2׳-deoxyguanosine-C13,N15; Phe-D5: phenylalanine-D5, Meth-D3: methionine-D3*.*

[^1]: Both authors have equally contributed.
